Adlai Nortye Ltd. ADS/$ANL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Adlai Nortye Ltd. ADS
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Ticker
$ANL
Sector
Primary listing
Employees
109
Headquarters
Website
ANL Metrics
BasicAdvanced
$460m
-
-$1.11
0.99
-
Price and volume
Market cap
$460m
Beta
0.99
52-week high
$17.25
52-week low
$0.88
Average daily volume
143k
Financial strength
Current ratio
0.646
Quick ratio
0.216
Long term debt to equity
-13.542
Total debt to equity
-316.943
Interest coverage (TTM)
-23.99%
Profitability
EBITDA (TTM)
-34.935
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-710.56%
Operating margin (TTM)
-713.96%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-42.21%
Return on equity (TTM)
-414.01%
Valuation
Price to revenue (TTM)
73.542
Price to book
-55.28
Price to tangible book (TTM)
-55.15
Price to free cash flow (TTM)
-10.931
Free cash flow yield (TTM)
-9.15%
Free cash flow per share (TTM)
-1.052
Growth
Earnings per share change (TTM)
-31.61%
3-year earnings per share growth (CAGR)
-45.68%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs